280 results on '"Leggio, Lorenzo"'
Search Results
2. Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder
3. Contributors
4. Gut microbial diversity and functional characterization in people with alcohol use disorder: A case-control study
5. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
6. Genetic or pharmacological GHSR blockade has sexually dimorphic effects in rodents on a high-fat diet
7. Granulocyte-colony stimulating factor use in alcohol-associated hepatitis: is it time to promote liver regeneration?
8. Amylin in Alcohol Addiction: A Potential New Treatment Target or an Adjuvant to Other Treatments?
9. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials
10. Lifetime use of alcohol and cannabis among U.S. adolescents across age: Exploring differential patterns by sex and race/ethnicity using the 2019 NSDUH data
11. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
12. Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin
13. Relationship between self-stigma about alcohol dependence and severity of alcohol drinking and craving
14. Pharmacological GHSR (ghrelin receptor) blockade reduces alcohol binge-like drinking in male and female mice
15. Genetic or pharmacological GHSR blockade has sexually dimorphic effects in rodents on a high-fat diet
16. Brain proteomic atlas of alcohol use disorder in adult males
17. Role of aldosterone and mineralocorticoid receptor (MR) in addiction: a scoping review
18. T102. IDENTIFYING NEW TREATMENT TARGETS FOR ALCOHOL USE DISORDER THROUGH GENETIC AND ELECTRONIC HEALTH RECORDS DATA APPROACHES
19. Sex difference in alcohol withdrawal syndrome: a scoping review of clinical studies
20. The adolescent and young adult microbiome and its association with substance use: a scoping review
21. Current and emerging pharmacotherapies for addiction treatment
22. A randomized controlled experimental medicine study of ghrelin in value-based decision making
23. Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder
24. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
25. 66. Pre-Clinical Insights: Ghrelin Receptor Blockade Reduces Binge-Like Alcohol Drinking in Male and Female Mice
26. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies
27. Investigating the relationship between early life adversity, inflammation and alcohol use
28. A human laboratory study on the link between alcohol administration and circulating fibroblast growth factor 21 (FGF21) in individuals with alcohol use disorder
29. The vicious cycle between (neuro)inflammation and alcohol use disorder: An opportunity to develop new medications?
30. Combined pharmacological and psychosocial interventions for alcohol use disorder
31. Alcohol use disorder in community management of chronic liver diseases
32. Initial Pharmacological Characterization of a Major Hydroxy Metabolite of PF-5190457: Inverse Agonist Activity of PF-6870961 at the Ghrelin Receptor
33. Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational crossover randomized trial
34. Hazardous drinking and alcohol use disorders
35. Oxytocin receptors mediate oxytocin potentiation of methylphenidate‐induced stimulation of accumbens dopamine in rats
36. Role of the ghrelin system in alcohol use disorder and alcohol‐associated liver disease: A narrative review
37. Simultaneous Management of Alcohol Use Disorder and of Liver Disease: A Systematic Review and Meta-analysis
38. Faculty Opinions recommendation of Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
39. Changes in plasma ghrelin levels following surgical and non-surgical weight-loss in female rats predict alcohol use
40. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
41. Faculty Opinions recommendation of FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit.
42. Alcohol Use Disorder
43. Advances in Pharmacotherapy Development: Human Clinical Studies
44. The Role of the Ghrelin System in Drug Addiction
45. Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use
46. The glucagon‐like peptide‐1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post‐mortem brain study
47. Echocardiographic markers of early alcoholic cardiomyopathy: Six-month longitudinal study in heavy drinking patients
48. The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder
49. The Need for Integrating Addiction Medicine and Hepatology
50. Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.